Pharmaceutical News

RSS

Efforts to contain drug-resistant malaria near Thai-Cambodian border appear to be working, officials say

A two-year effort aimed at preventing the emergence of drug-resistant malaria near the border between Cambodia and Thailand is showing signs of success, Duong Socheat, head of Cambodia's National Center for Malaria Control, said on Friday, DPA/Earth Times reports.

29 Jun 2010

Ahead of International AIDS Conference, health experts call for scientifically-based drug policies

Ahead of the International AIDS Conference, scheduled to kick off July 18, health experts on Monday called for a rethinking of international drug policies to incorporate greater scientific evidence and increase access to HIV prevention, treatment and care, the Associated Press reports (6/28).

29 Jun 2010

Sunridge International delivers 60 PNT Units and 10,000 disposable rings to BV of China

Sunridge International, announced today that it has completed production and delivery of 60 PNT Units and 10,000 disposable rings to its exclusive distributor, Beijing Vision World Trading Company (BV) of China.

28 Jun 2010

FDA grants Tarix's TXA127 Orphan Drug designation for stem cell engraftment and treatment of MDS

Tarix Pharmaceuticals today announced that it's drug, TXA127, has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) as a treatment to enhance engraftment in patients receiving a stem cell transplant. TXA127 has also received Orphan Drug designation for the treatment of Myelodysplastic Syndrome (MDS).

28 Jun 2010

ULURU, Strakan International divest interest in Zindaclin to Crawford Healthcare subsidiary

ULURU Inc. announced today that Strakan International Limited and ULURU have divested their respective interest in Zindaclin® to a subsidiary of Crawford Healthcare Limited, a pharmaceutical company based in England. Zindaclin® is a product for the treatment of acne which is outside the strategic focus of ULURU. This product was included in the technology package ULURU acquired when it was formed in 2005.

28 Jun 2010

Marinomed, Boehringer Ingelheim sign licensing agreement for common cold anti-viral nasal spray

Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, announced today that it has signed a licensing agreement with the international pharmaceutical company Boehringer Ingelheim. The deal will aim to further extend marketing of Marinomed's anti-viral nasal spray for the treatment of the Common Cold to all of Europe (except Austria and UK), Russia and CIS, South America, parts of Asia and Australia.

28 Jun 2010

Pain Therapeutics modifies strategic alliance with King Pharmaceuticals for REMOXY outside U.S.

Pain Therapeutics, Inc. announced today a modification of its strategic alliance with King Pharmaceuticals, Inc. for REMOXY outside the U.S. The move signals a desire to target Europe's small and growing market for strong pain medications.

28 Jun 2010

Boston Therapeutics submits structure, function claims of SUGARDOWN to FDA

Boston Therapeutics, Inc. has announced that it has submitted structure and function claims of its SUGARDOWN™ to the US Food and Drug Administration on June 21, 2010.

28 Jun 2010

Aestus Therapeutics announces license agreement with Astellas Pharma

Aestus Therapeutics, Inc. announced today a license agreement with Astellas Pharma Inc. (Astellas; Tokyo, Japan) to provide Aestus with exclusive, world-wide rights to the Astellas product FK614. Aestus will develop the product as ATx08-001, a novel, first-in-class therapeutic for the treatment of neuropathic pain. The first clinical trial will start later this year.

28 Jun 2010

EMA CHMP recommends marketing approval of BRINAVESS for conversion of recent onset AF to sinus rhythm

Merck and Cardiome Pharma Corp. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing approval for BRINAVESS® (vernakalant), an investigational intravenous (IV) formulation for the conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults.

28 Jun 2010

AHF rejects Obama trial balloon of $30M for nation's ADAP

AIDS Healthcare Foundation, the largest global AIDS organization, is rejecting a trial balloon floated by Obama Administration officials that suggests $30 million in additional funding could adequately help close a gaping $126 million hole in funding for the nation's AIDS Drug Assistance Program, the federal and state funded, state run network of assistance programs that supply lifesaving AIDS drugs to low-income Americans in need.

28 Jun 2010

Merck challenges New York jury decision in federal FOSAMAX retrial

Merck & Co., Inc. today said it is challenging the decision returned by a New York jury in the retrial of a federal FOSAMAX case, Boles v. Merck. This case was the Plaintiffs' Steering Committee's top choice to take to trial and involved a Florida woman who blamed her dental and jaw problems on FOSAMAX. The first case to reach a verdict, Maley v. Merck, resulted in a defense verdict for Merck on May 5, 2010.

28 Jun 2010

EVISTA improves bone quality as measured by HRpQCT: IIT

Interim data from a prospective Investigator Initiated Trial presented today at the ECTS, the 37th European Symposium on Calcified Tissues, in Glasgow, demonstrates that EVISTA (raloxifene 60mg; once-daily, distributed in 34 countries by DAIICHI SANKYO), indicated for the treatment and prevention of osteoporosis in postmenopausal women, improves bone quality as measured by the high-resolution peripheral quantitative computed tomography.

28 Jun 2010

WellPoint research leads to limits on use of Boniva; FDA spars with tobacco company

"WellPoint Inc. (WLP), the largest U.S. managed-care concern by membership, made it harder last year for its members to gain approval for use of the Boniva osteoporosis drug after internal research linked it to higher fracture rates, lower patient compliance and higher total costs of care than two other drugs, a WellPoint executive said Thursday," Dow Jones Newswires/The Wall Street Journal reports.

28 Jun 2010

Combination MMRV vaccine associated with increased risk of febrile seizures

The combination vaccine for measles, mumps, rubella and chickenpox (MMRV) is associated with double the risk of febrile seizures for 1- to 2-year-old children compared with same-day administration of the separate vaccine for MMR (measles, mumps, rubella) and the varicella (V) vaccine for chicken pox, according to a Kaiser Permanente Division of Research study appearing online in the journal Pediatrics. A febrile seizure is a brief, fever-related convulsion but it does not lead to epilepsy or seizure disorders, researchers explained.

28 Jun 2010

Poster presentation at MASCC Conference summarizes MuGard clinical experience

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, is presenting a scientific poster today at the Multinational Association of Supportive Care in Cancer Conference in Vancouver, B.C. The poster presentation, co-authored by Dr. David Nowotnik of Access Pharmaceuticals and Dr. Caroline Dumas of SpePharm Holdings, summarizes MuGard clinical experience from cancer patients globally undergoing radiotherapy and/or chemotherapy.

28 Jun 2010

FDA grants orphan drug designation for Chiasma's Octreolin

Chiasma, Inc., a privately held biopharma company, announced that the Food and Drug Administration has granted orphan drug designation for Chiasma's investigational new drug, Octreolin, an oral form of octreotide acetate that uses the Company's proprietary Transient Permeability Enhancer technology for the oral treatment of acromegaly, a hormonal disorder that results from an excess of growth hormone.

28 Jun 2010

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET (sitagliptin/metformin) to pioglitazone. In this study, JANUMET resulted in significantly greater blood sugar reductions in patients with type 2 diabetes compared with pioglitazone.

28 Jun 2010

Antioxidant therapy may prevent long-lasting cognitive impairment in cerebral malaria: Research

Using an experimental mouse model for malaria, an international group of scientists has discovered that adding antioxidant therapy to traditional antimalarial treatment may prevent long-lasting cognitive impairment in cerebral malaria. Their findings were published online June 24, 2010, in the journal PLoS Pathogens.

28 Jun 2010

Data on MetAP2 inhibitors for treatment of obesity presented at ADA 2010

Zafgen, Inc., a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced data on ZGN-201, a prototype methionine aminopeptidase 2 inhibitor, for the treatment of obesity. Preclinical studies demonstrate MetAP2 inhibition eliminates excess body weight through the regulation of fat metabolism and food intake, and normalizes glucose tolerance in animal models.

28 Jun 2010

Pharmaceutical News

Efforts to contain drug-resistant malaria near Thai-Cambodian border appear to be working, officials say

Ahead of International AIDS Conference, health experts call for scientifically-based drug policies

Sunridge International delivers 60 PNT Units and 10,000 disposable rings to BV of China

FDA grants Tarix's TXA127 Orphan Drug designation for stem cell engraftment and treatment of MDS

ULURU, Strakan International divest interest in Zindaclin to Crawford Healthcare subsidiary

Marinomed, Boehringer Ingelheim sign licensing agreement for common cold anti-viral nasal spray

Pain Therapeutics modifies strategic alliance with King Pharmaceuticals for REMOXY outside U.S.

Boston Therapeutics submits structure, function claims of SUGARDOWN to FDA

Aestus Therapeutics announces license agreement with Astellas Pharma

EMA CHMP recommends marketing approval of BRINAVESS for conversion of recent onset AF to sinus rhythm

AHF rejects Obama trial balloon of $30M for nation's ADAP

Merck challenges New York jury decision in federal FOSAMAX retrial

EVISTA improves bone quality as measured by HRpQCT: IIT

WellPoint research leads to limits on use of Boniva; FDA spars with tobacco company

Combination MMRV vaccine associated with increased risk of febrile seizures

Poster presentation at MASCC Conference summarizes MuGard clinical experience

FDA grants orphan drug designation for Chiasma's Octreolin

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

Antioxidant therapy may prevent long-lasting cognitive impairment in cerebral malaria: Research

Data on MetAP2 inhibitors for treatment of obesity presented at ADA 2010

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News